Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OlaHsd mice-influence of treatment with the CRHR1-antagonist R121919/NBI 30775

Journal of Psychopharmacology

Volumn 23, Issue 1, 2009, Pages 31-39

  Erhardt, A ^a   Muller M B ^a   Rodel A ^a   Welt, T ^a,b   Ohl, F ^a,c   Holsboer, F ^a   Keck, M E ^a,d  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Centre of Neuroscience Research Zurich   (Switzerland)

Author keywords

Chronic social defeat; CRHR1 antagonist; DBA 2OlaHsd mice; Hole board test; PVN; Vasopressin

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ARGIPRESSIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ANTAGONIST; MESSENGER RNA; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DEPRESSION; EMOTIONALITY; EVENING DOSAGE; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; INDIVIDUALIZATION; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SOCIAL STRESS; SUPRAOPTIC NUCLEUS; THALAMUS MIDLINE NUCLEUS; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; AGGRESSION; ANIMALS; ARGININE VASOPRESSIN; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; GENE EXPRESSION; MALE; MICE; MICE, INBRED DBA; NERVE NET; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PYRIMIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, MESSENGER; STRESS, PSYCHOLOGICAL; SUPRAOPTIC NUCLEUS;

EID: 58649121451     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089813     Document Type: Article

References (46)

1. Aguilera, G., Rabadan-Diehl, C. (2000) Vasopressinergic regulation of the hypothalamic-pituitary- adrenal axis: implications for stress adaptation. Regul Pept 96: 23-29.
2. Antoni, FA (1993) Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14: 76-122.
3. Arborelius, L., Owens, MJ, Plotsky, PM, Nemeroff, CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160: 1-12.
4. Bhatnagar, S., Vining, C., Iyer, V., Kinni, V. (2006) Changes in hypothalamic-pituitary-adrenal function, body temperature, body weight and food intake with repeated social stress exposure in rats. J Neuroendocrinol 18: 13-24.
5. Bjorkqvist, K. (2001) Social defeat as a stressor in humans. Physiol Behav 73: 435-442.
6. Blanchard, RJ, McKittrick, CR, Blanchard, DC (2001) Animal models of social stress: Effects on behavior and brain neurochemical systems. Physiol Behav 73: 261-271.
7. Caspi, A., Sugden, K., Moffitt, TE, Taylor, A., Craig, IW, Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., Poulton, R. (2003) Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301: 386-389.
8. Chaouloff, F., Durand, M., Mormede, P. (1997) Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/ dark and dark/light tests. Behav Brain Res 85: 27-35.
9. Chen, C., Grigoriadis, DE (2005) NBI 30775 (R121919). an orally active antagonist of the corticotropin-releasing factor (CRF) type-1 receptor for the treatment of anxiety and depression. Drug Dev Res 65: 216-226.
10. Chen, C., Wilcoxen, KM, Huang, CQ, Xie, YF, McCarthy, JR, Webb, TR, Zhu, YF, Saunders, J., Liu, XJ, Chen, TK, Bozigian, H., Grigoriadis, DE (2004) Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazol o[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J Med Chem 47: 4787-4798.
11. de Kloet, ER, Joels, M., Holsboer, F. (2005) Stress and the brain: From adaptation to disease. Nat Rev Neurosci 6: 463-475.
12. Ebner, K., Wotjak, CT, Landgraf, R., Engelmann, M. (2002) Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats. Eur J Neurosci 15: 384-388.
13. Engelmann, M., Wotjak, CT, Neumann, I., Ludwig, M., Landgraf, R. (1996) Behavioral consequences of intracerebral vasopressin and oxytocin: Focus on learning and memory. Neurosci Biobehav Rev 20: 341-358.
14. Erhardt, A., Ising, M., Unschuld, PG, Kern, N., Lucae, S., Putz, B., Uhr, M., Binder, EB, Holsboer, F., Keck, ME (2006) Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology 31: 2515-2522.
15. Gutman, DA, Owens, MJ, Skelton, KH, Thrivikraman, KV, Nemeroff, CB (2003) The corticotropin-releasing factor(1) receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 304: 874-880.
16. Heinrichs, SC, De Souza, EB, Schulteis, G., Lapsansky, JL, Grigoriadis, DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27: 194-202.
17. Held, K., Kunzel, H., Ising, M., Schmid, DA, Zobel, A., Murck, H., Holsboer, F., Steiger, A. (2004) Treatment with the C RH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 38: 129-136.
18. Holsboer, F. (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
19. Holsboer, F. (2001) Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 62: 77-91.
20. Holsboer, F. (2003) High-quality antidepressant discovery by understanding stress hormone physiology. Ann N Y Acad Sci 1007: 394-404.
21. Jaccard, J., Becker, MA, Wood, G. (1984) Pairwise Multiple Comparison Procedures - a Review. Psychol Bull 96: 589-596.
22. Keck, ME, Ohl, F., Holsboer, F., Muller, MB (2005) Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neurosci Biobehav Rev 29: 867-889.
23. Keck, ME, Welt, T., Muller, MB, Landgraf, R., Holsboer, F. (2003 a) The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry 36: 27-31.
24. Keck, ME, Welt, T., Muller, MB, Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., Landgraf, R. (2003 b) Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28: 235-243.
25. Keck, ME, Welt, T., Wigger, A., Renner, U., Engelmann, M., Holsboer, F., Landgraf, R. (2001) The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13: 373-380.
26. Keeney, A., Jessop, DS, Harbuz, MS, Marsden, CA, Hogg, S., Blackburn-Munro, RE (2006) Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice. J Neuroendocrinol 18: 330-338.
27. Kendler, KS, Kuhn, JW, Vittum, J., Prescott, CA, Riley, B. (2005) The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression - A replication. Arch Gen Psychiatry 62: 529-535.
28. Kuenzel, HE, Zobel, AW, Nickel, T., Ackl, N., Uhr, M., Ising, M., Sonntag, A., Holsboer, F. (2001) Treatment with the CRH-1-receptor antagonist R121919 shows a high safety in the HPA system and clinical routine. Biol Psychiatry 49: 51S - 51S.
29. Martin, P. (1998) Animal models sensitive to anti-anxiety agents. Acta Psychiatr Scand 98: 74-80.
30. Martinez, M., Calvo-Torrent, A., Pico-Alfonso, MA (1998) Social defeat and subordination as models of social stress in laboratory rodents: A review. Aggress Behav 24: 241-256.
31. Merali, Z., Kent, P., Du, LS, Hrdina, P., Palkovits, M., Faludi, G., Poulter, MO, Bedard, T., Anisman, H. (2006) Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol Psychiatry 59: 594-602.
32. Muller, MB, Zimmermann, S., Sillaber, I., Hagemeyer, TP, Deussing, JM, Timpl, P., Kormann, MSD, Droste, SK, Kuhn, R., Reul, J., Holsboer, F., Wurst, W. (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6: 1100-1107.
33. Nakase, S., Kitayama, I., Soya, H., Hamanaka, K., Nomura, J. (1998) Increased expression of magnocellular arginine vasopressin mRNA in paraventricular nucleus of stress-induced depression-model rats. Life Sci 63: 23-31.
34. Nemeroff, CB, Vale, WW (2005) The neurobiology of depression: Inroads to treatment and new drug discovery. J Clin Psychiatry 66: 5-13.
35. Nestler, EJ, Barrot, M., DiLeone, RJ, Eisch, AJ, Gold, SJ, Monteggia, LM (2002) Neurobiology of depression. Neuron 34: 13-25.
36. Ohl, F. (2003) Testing for anxiety. Clin Neurosci Res 3: 233-238.
37. Ohl, F., Holsboer, F., Landgraf, R. (2001 a) The modified hole board as a differential screen for behavior in rodents. Behav Res Methods Instrum Comput 33: 392-397.
38. Ohl, F., Roedel, A., Binder, E., Holsboer, F. (2003) Impact of high and low anxiety on cognitive performance in a modified hole board test in C57BL/6 and DBA/2 mice. Eur J Neurosci 17: 128-136.
39. Ohl, F., Toschi, N., Wigger, A., Henniger, MSH, Landgraf, R. (2001 b) Dimensions of emotionality in a rat model of innate anxiety. Behav Neurosci 115: 429-436.
40. Pariante, CM, Miller, AH (2001) Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404.
41. Post, A., Ohl, F., Almeida, OFX, Binder, EB, Rucker, M., Welt, S., Binder, E., Holsboer, F., Sillaber, I. (2005) Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Psychopharmacology 180: 150-158.
42. Raadsheer, FC, Hoogendijk, WJG, Stam, FC, Tilders, FJH, Swaab, DF (1994) Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed-Patients. Neuroendocrinology 60: 436-444.
43. Schmidt, M., Oitzl, MS, Muller, MB, Ohl, F., Wurst, W., Holsboer, F., Levine, S., De Kloet, ER (2003) Regulation of the developing hypothalamic-pituitary-adrenal axis in corticotropin releasing hormone receptor 1-deficient mice. Neuroscience 119: 589-595.
44. Smith, GW, Aubry, JM, Dellu, F., Contarino, A., Bilezikjian, LM, Gold, LH, Chen, RP, Marchuk, Y., Hauser, C., Bentley, CA, Sawchenko, PE, Koob, GF, Vale, W., Lee, KF (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
45. Welt, T., Engelmann, M., Renner, U., Erhardt, A., Muller, MB, Landgraf, R., Holsboer, F., Keck, ME (2006) Temazepam triggers the release of vasopressin into the rat hypothalamic paraventricular nucleus: Novel insight into benzodiazepine action on hypothalamic-pituitary-adrenocortical system activity during stress. Neuropsychopharmacology 31: 2573-2579.
46. Zobel, AW, Nickel, T., Kunzel, HE, Ackl, N., Sonntag, A., Ising, M., Holsboer, F. (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171-181.